Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 19/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 19/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 19/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 19/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 19/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 19/20 | 0.47 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3033357 | 1.00 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Methyl Alcohol SCHEMBL28457179 | 0.96 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18878187 | 0.94 | L3MBTL1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18675295 | 0.85 | — | — | |
| SCHEMBL3738800 | 0.85 | — | — | |
| SCHEMBL29346027 | 0.82 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29346218 | 0.80 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL11338976 | 0.79 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22838139 | 0.78 | L3MBTL1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18884373 | 0.78 | L3MBTL1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173747-B1 | A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI SA (FR) | 2011-12-21 | — | — | EP | disclosed |
| US-20100216988-A1 | Regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2010-08-26 | — | — | US | disclosed |
| EP-2173747-A1 | A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES | Sanofi-Aventis (FR) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009000412-A1 | A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI AVENTIS (FR) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216988-A1 | Regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles | AZI2, NIT2, NISCH | PSEN1 4472/4885PSEN2 4125/4885APH1B 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.